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Abstract Accumulation of carbonyl derivatives of proteins
(protein carbonyl) is taken as a biomarker of oxidative protein
damage in aging and in various diseases. We detected protein
carbonyls in situ in human diabetic arteriosclerotic tissues and
characterized the formation of protein carbonyls. Protein
carbonyls were identified in the thickened intima of arterial
walls and co-localized with protein adducts formed by carbonyl
amine chemistry between protein and carbonyl compounds
derived from autoxidation of carbohydrates, lipids, and ascor-
bate, i.e. advanced glycation end products or glycoxidation
products, such as carboxymethyllysine (CML) and pentosidine,
and lipoxidation products, such as malondialdehyde (MDA) and
4-hydroxy-nonenal (HNE). In vitro incubation of proteins with
ascorbic acid accelerated the production of protein carbonyls as
well as CML and pentosidine, and incubation with arachidonate
accelerated the production of protein carbonyls as well as CML,
MDA, and HNE. By contrast, incubation of proteins with
glucose resulted in the production of CML and pentosidine, but
not protein carbonyls. Schiff base inhibitors, ( þ )-2-isopropyl-
idenehydrazono-4-oxo-thiazolidin-5-ylacetanilide and aminogua-
nidine, inhibited the production of protein carbonyls after
incubation with ascorbate and arachidonate. The present study
suggests that ascorbate and polyunsaturated fatty acids, but not
glucose, represent potential sources of protein carbonyls, and
that both the glycoxidation and lipoxidation reactions contribute
to protein carbonyl formation in aging and various diseases.
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1. Introduction
Accumulation of protein carbonyls is implicated in aging
[1,2]. Relationships have been found between the content of
protein carbonyls and cell age in human erythrocytes and in
cultured ¢broblasts [3], and between the content of protein
carbonyls and subject age in human brain and in lens tissues
[4,5]. Also in various diseases, rises in protein carbonyls have
been demonstrated [4^7].
Several lines of evidence have demonstrated that protein
carbonyls are generated in vivo primarily by the metal-cata-
lyzed oxidation systems [1,2]. Other mechanisms of protein
carbonyl formation are not fully understood. Furthermore,
the histological distribution of protein carbonyls in diseases
has been determined only in the brain tissues of patients with
Alzheimer’s disease [8] and remains to be established in other
diseases.
Under oxidative stress, carbohydrates and lipids as well as
proteins are the major targets of reactive oxygen species. Pro-
teins are modi¢ed indirectly with reactive carbonyl com-
pounds derived from the autoxidation of carbohydrates and
lipids. Autoxidation of carbohydrates and ascorbate yields
carbonyl compounds, e.g. glyoxal, arabinose, methylglyoxal,
glycolaldehyde, and dehydroascorbate [9^12]. These carbonyls
are reactive with protein amino groups and initiate the Mail-
lard reaction which forms Schi¡ base and eventually advanced
glycation end products (AGEs) or glycoxidation products,
such as NO-carboxymethyllysine (CML) and pentosidine. Lip-
id peroxidation of polyunsaturated fatty acids, such as arach-
idonate, yields other carbonyl compounds: some are identical
to those formed from carbohydrates [13], such as glyoxal and
methylglyoxal, and others are characteristic of lipids, such as
malondialdehyde (MDA) and 4-hydroxy-nonenal (HNE) [14].
The latter carbonyl compounds produce lipoxidation prod-
ucts, MDA-lysine and HNE-protein adducts [15,16]. It is of
interest that the accumulation of glycoxidation and lipoxida-
tion products in the serum and tissue proteins has been im-
plicated in diseases similar to those with an increase in protein
carbonyls [17^26].
We therefore hypothesized that both glycoxidation and lip-
oxidation reactions contribute to the formation of protein
carbonyls. To test this, we detected protein carbonyls as
well as glycoxidation and lipoxidation products in human
diabetic arteriosclerotic tissues. Furthermore, we characterized
the in vitro formation of protein carbonyls as well as glyc-
oxidation and lipoxidation products.
2. Materials and methods
2.1. Human tissue specimens
Arterial tissue sections were obtained at autopsy from seven pa-
tients with non-insulin-dependent diabetic mellitus with poor glycemic
control (hemoglobin A1C, s 8%) (age 42^59). These specimens were
¢xed in 10% formalin and embedded in para⁄n.
2.2. Antibodies
Anti-pentosidine rabbit IgG [21], anti-HNE rabbit IgG [27], and
anti-MDA mouse monoclonal IgG (kindly provided from Dr. Joseph
L. Witztum) [28,29] were used for immunohistochemistry. Anti-AGE
rabbit IgG [26], the major epitope structure of which was recently
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identi¢ed as CML [30], was also used. These antibodies were highly
speci¢c as demonstrated by minimal cross-reactivity assessed by com-
petition with albumin modi¢ed with related epitopes [20].
2.3. Immunohistochemistry
Tissue sections (5 Wm thickness) were mounted on a slide coated
with 3-aminopropyltriethoxysilane (Sigma, St. Louis, MO), depara⁄-
nized, and rehydrated in distilled water. For in situ detection of pro-
tein carbonyls, tissue sections were incubated with 0.5 mg/ml pronase
(Dako, Glostrup, Denmark) for 5 min at room temperature and, after
washing, reacted with or without 2,4-dinitrophenylhydrazine for 5 min
at room temperature to derivatize protein carbonyl groups to 2,4-
dinitrophenylhydrazone (DNP-hydrazone), followed by further incu-
bation with 1:50 diluted rabbit anti-DNP antibody (Oncor, Gaithers-
burg, MD) for 2 h. The sections were washed and incubated with
1:100 diluted goat anti-rabbit IgG conjugated with peroxidase
(Dako) for 2 h, followed by the detection with 3,3P-diaminobenzidine
solution containing 0.003% H2O2. To con¢rm the speci¢city of im-
munostaining, competition experiment was performed by preincuba-
tion of tissue sections with 10 mM sodium borohydride for 30 min
before 2,4-dinitrophenylhydrazine reaction. Non-immune rabbit IgG
was used as a negative control.
For detection of glycoxidation and lipoxidation products, tissue
sections were incubated with either anti-AGE (CML) rabbit IgG,
anti-pentosidine rabbit IgG, anti-MDA mouse monoclonal IgG, or
anti-HNE rabbit IgG overnight in humid chambers at room temper-
ature, followed by incubation with goat anti-rabbit or -mouse IgG
conjugated with peroxidase and the detection with 3,3P-diaminobenzi-
dine and H2O2, as described above. The speci¢city of immunostaining
was con¢rmed by competition experiments by incubating anti-AGE,
anti-pentosidine, anti-HNE, or anti-MDA antibody for 4 h at 37‡C
with an excess of CML-, pentosidine-, MDA-, or HNE-BSA, respec-
tively [20]. Non-immune rabbit or mouse IgG was used as a negative
control.
2.4. In vitro incubation experiments
Fatty acid-free BSA (10 mg) was incubated at 37‡C under air with
either 100 mM glucose, 10 mM ascorbic acid, or 10 mM arachidonate
(Sigma) in 5.0 ml of 0.1 M sodium phosphate bu¡er (pH 7.4), in the
absence or presence of several concentrations of OPB-9195 [31] or
aminoguanidine (Tokyo Chemical Industry, Tokyo, Japan) [32]. The
experiment was repeated twice.
The protein carbonyl content was measured by the method as pre-
viously reported [16]. CML in the hydrolysates was measured as its N-
tri£uoroacetate methyl ester by selected ion monitoring gas chroma-
tography/mass spectrometry (GC/MS), as described previously [33].
The CML standard [34] was a gift from Dr. John W. Baynes. Pento-
sidine was measured in hydrolysates of the incubation mixtures by
reversed-phase high performance chromatographic assay using post-
column £uorescence detection (Ex = 328 nm, Em = 378 nm) [21,35].
The preparation of pentosidine standard has been described previ-
ously [35]. MDA was measured using a colorimetric assay kit (Bio-
xyteckh LPO-586: Oxis International, Portland, OR). HNE was de-
termined by an ELISA as described previously [36].
2.5. Statistical analysis
Data are expressed as means þ S.D. IC50 was calculated using re-
gression analysis.
3. Results
3.1. Co-localization of protein carbonyls with glycoxidation and
lipoxidation products in diabetic arteriosclerosis
Diabetic arteriosclerotic lesions were examined for protein
carbonyls. Protein carbonyls were identi¢ed in di¡usely thick-
ened intima (neointima) of arterial walls (Fig. 1A). No protein
carbonyls was detected in control tissue sections processed
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Fig. 1. Immunohistochemical detection of protein carbonyls as well as glycoxidation and lipoxidation products in diabetic arteriosclerosis. Arte-
riosclerotic tissue sections from a 54-year-old non-insulin-dependent diabetic male were immunostained for protein carbonyls (A and B), CML
(C), pentosidine (D), MDA (E), and HNE (F). Nuclei were counterstained with Meyer’s hematoxylin. Protein carbonyls are present in the dif-
fusely thickened intima of arterial walls (indicated by arrows in A), but are undetectable in control tissue section processed usnder the same
conditions except for the absence of the 2,4-dinitrophenylhydrazine reaction (B). Protein carbonyls co-localize with the glycoxidation and lipoxi-
dation products. A^F, U200.
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under the same conditions except for the absence of the 2,4-
dinitrophenylhydrazine reaction (Fig. 1B) or in tissue sections
preincubated with sodium borohydrate before 2,4-dinitro-
phenylhydrazine reaction (data not shown). The distribution
of protein carbonyls coincided with those of two glycoxida-
tion products, CML (Fig. 1C) and pentosidine (Fig. 1D), and
two lipoxidation products, MDA (Fig. 1E) and HNE (Fig.
1F). Speci¢city of immunostainings was demonstrated by
the absence of immunoreaction with non-immune mouse or
rabbit IgG or in the presence of an excess of competitors
(data not shown).
3.2. In vitro formation of protein carbonyls as well as
glycoxidation and lipoxidation products
To characterize the formation of protein carbonyls on pro-
teins, BSA was incubated under air with glucose, arachido-
nate, or ascorbic acid, all of which are autoxidized and yield
carbonyl compounds capable of reacting with proteins. Incu-
bation of BSA with glucose (Fig. 2A) and ascorbate (Fig. 2B)
yielded a time-dependent increase of glycoxidation products,
CML and pentosidine, but not of lipoxidation products,
MDA and HNE. Incubation of BSA with arachidonate
yielded an increase of CML, MDA, and HNE, but not of
pentosidine (Fig. 2C). It is noted that incubation with ascor-
bate as well as arachidonate yielded protein carbonyls (closed
circles in Fig. 2). By contrast, protein carbonyls were not
detectable after a 4 week incubation with glucose.
Schi¡ base inhibitors, OPB-9195 and aminoguanidine, in-
hibit both the glycoxidation and lipoxidation reactions, be-
cause their hydrazine nitrogen atoms are capable of trapping
reactive carbonyl compounds, directly or via the free base
upon hydrolysis, by the hydrazone formation (unpublished).
Therefore, the involvement of glycoxidation and lipoxidation
reactions in the formation of protein carbonyls was further
evaluated using these Schi¡ base inhibitors. OPB-9195 inhib-
ited in a dose-dependent manner the formation of protein
carbonyls after incubation with ascorbate and arachidonate:
half-maximal inhibition (IC50) was observed at an OPB-9195
concentration of 2.13 mM for ascorbate-derived protein car-
bonyls (Fig. 3A) and of 0.64 mM for arachidonate-derived
protein carbonyls (Fig. 3B). The corresponding ¢gure for ami-
noguanidine was 5.87 mM for arachidonate-derived protein
carbonyl formation. The lower e⁄cacy of aminoguanidine is
further illustrated by the fact that even 10 mM aminoguani-
dine achieved only 29.4% inhibition of ascorbate-derived pro-
tein carbonyl formation. The enhanced e¡ectiveness of OPB-
9195 might be due to the fact that the hydrazine nitrogen
atom of aminoguanidine has decreased nucleophilicity be-
cause of the adjacent guanidinium cation (unpublished).
4. Discussion
We provide evidence suggesting that both the glycoxidation
and lipoxidation reactions contribute to the increase in pro-
tein carbonyls. First, protein carbonyls were identi¢ed in co-
localization with both the glycoxidation and lipoxidation
products in the thickened intima of diabetic arterial walls.
Second, the glycoxidation and lipoxidation reactions of BSA
with ascorbic acid and arachidonate accelerated the produc-
tion of protein carbonyls in addition to the glycoxidation and
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Fig. 2. In vitro formation of protein carbonyls as well as glycoxida-
tion and lipoxidation products. BSA (10 mg) was incubated at 37‡C
with either 100 mM glucose (A), 10 mM ascorbic acid (B), or 10
mM arachidonate (C) in 0.1 M phosphate bu¡er (pH 7.4), and the
yields of protein carbonyls, CML, pentosidine, MDA, and HNE in
the incubation mixtures were determined at intervals. The protein
carbonyl content in the control BSA incubated for 4 weeks without
precursors is 8.26 nmol/mg albumin and the levels of CML, pentosi-
dine, MDA, and HNE in the control BSA incubated for 4 weeks
without precursors are below the detection limits. b, protein carbon-
yls; a, CML; O, pentosidine; E, MDA; P, HNE. Representative
data from two experiments are shown. Data are expressed as
means þ S.D.
Fig. 3. Inhibitory e¡ect of OPB-9195 in vitro on the formation of
protein carbonyls in BSA. BSA (10 mg) was incubated under air at
37‡C for 4 weeks with either 10 mM ascorbate (A) or arachidonate
(B) in 0.1 M phosphate bu¡er (pH 7.4) in the presence of several
concentrations of OPB-9195. The yields of protein carbonyls in the
incubation mixtures were then determined. Representative data from
two experiments are shown. Data are expressed as means þ S.D.
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lipoxidation products. Finally, inhibitors of the glycoxidation
and lipoxidation reactions, OPB-9195 and aminoguanidine,
inhibited the production of protein carbonyls after incubation
with ascorbate and arachidonate.
That protein carbonyls as well as glycoxidation and lipoxi-
dation products originate from the glycoxidation and lipoxi-
dation reactions can account for the simultaneous accumula-
tion of protein carbonyls, and glycoxidation and lipoxidation
products in aging and various diseases, e.g. atherosclerosis,
diabetes, uremia, rheumatoid arthritis, cataractogenesis, and
neurologic disorders.
Oxygen free radicals produced by the metal catalyzed oxi-
dation systems have been assumed as the primary mechanism
for the formation of protein carbonyls in vivo [1,2]. Protein
carbonyls are also generated by oxygen free radicals produced
by ionizing radiation [37]. The present conclusion that both
glycoxidation and lipoxidation reactions contribute to the in-
crease in protein carbonyls, is in good agreement with the
assumption by Stadtman [1] that glycation or Maillard reac-
tion may contribute to the formation of protein carbonyls.
However, glucose, which is the major source of glycation or
Maillard reaction in vivo, turned out not to represent the
source of protein carbonyls. Unexpectedly, ascorbate and
polyunsaturated fatty acids represented potential sources of
protein carbonyls. Of course, most careful consideration
would be required to assess the formation of protein carbon-
yls in vivo, taking into account the concentration of each
source and the duration of protein exposure to each source.
It remains unknown to what extent the glycoxidation and
lipoxidation reactions contribute to the formation of protein
carbonyls in vivo, as compared to the metal-catalyzed oxida-
tion systems. At present, it is di⁄cult to assess the con-
tribution of each mechanism to the observed age-related in-
crease and in various diseases. Further development of
analytical procedures will be required to address this issue
of interest.
Smith et al. [8] reported the histological distribution of pro-
tein carbonyls in the neuronal cytoplasm and nuclei of neu-
rons and glia, and in neuro¢brillary tangles in brain tissues of
patients with Alzheimer’s disease. In this regard, of particular
interest are recent ¢ndings by us and others that glycoxidation
products, CML and pentosidine, and lipoxidation products,
MDA and HNE, were identi¢ed immunohistochemically in
the neuronal cytoplasm and in neuro¢brillary tangles in brain
tissues of patients with Alzheimer’s disease [24,25,29,30].
We demonstrated the distribution of protein carbonyls for
the ¢rst time in vascular lesions, i.e. in diabetic arteriosclero-
sis. Our preliminary studies identi¢ed protein carbonyls also
in the thickened intima of arterial walls of senile atheroscle-
rosis and uremic arteriosclerosis, in co-localization with the
glycoxidation and lipoxidation products (our unpublished ob-
servation). Therefore, the accumulation of protein carbonyls
in vascular lesions might be a phenomenon common in most,
not if all, types of vascular damage.
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